Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project.
Sebri V, Marzorati C, Dorangricchia P, Monzani D, Grasso R, Prelaj A, Provenzano L, Mazzeo L, Dumitrascu AD, Sonnek J, Szewczyk M, Watermann I, Trovò F, Dollis N, Sarris E, Garassino MC, Bestvina CM, Pedrocchi A, Ambrosini E, Kosta S, Felip E, Soleda M, Roca AA, Rodríguez-Morató J, Nuara A, Lourie Y, Fernandez-Pinto M, Aguaron A, Pravettoni G. Sebri V, et al. Among authors: garassino mc. Cancer Med. 2024 May;13(9):e7159. doi: 10.1002/cam4.7159. Cancer Med. 2024. PMID: 38741546 Free PMC article. Review.
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepetis R, Wu X, Fandi A, Paz-Ares L. Levy BP, et al. Among authors: garassino mc. Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14. Eur J Cancer. 2019. PMID: 30654297 Clinical Trial.
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. Galli G, et al. Among authors: garassino mc. Lung Cancer. 2019 Nov;137:38-42. doi: 10.1016/j.lungcan.2019.08.030. Epub 2019 Sep 10. Lung Cancer. 2019. PMID: 31526910 Free article.
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.
Nichetti F, Ligorio F, Zattarin E, Signorelli D, Prelaj A, Proto C, Galli G, Marra A, Apollonio G, Porcu L, de Braud F, Lo Russo G, Ferrara R, Garassino MC. Nichetti F, et al. Among authors: garassino mc. Cancers (Basel). 2019 Dec 25;12(1):67. doi: 10.3390/cancers12010067. Cancers (Basel). 2019. PMID: 31881699 Free PMC article.
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.
Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Trevisan B, Trovò F, Torri V, Sozzi G, Garassino MC, Boeri M. Prelaj A, et al. Among authors: garassino mc. Transl Lung Cancer Res. 2020 Jun;9(3):617-628. doi: 10.21037/tlcr-20-231. Transl Lung Cancer Res. 2020. PMID: 32676324 Free PMC article.
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
Lobefaro R, Viscardi G, Di Liello R, Massa G, Iacovino ML, Sparano F, Della Corte CM, Ferrara R, Signorelli D, Proto C, Prelaj A, Galli G, De Toma A, Brambilla M, Ganzinelli M, Trevisan B, Ciardiello F, De Braud F, Morgillo F, Garassino MC, Lo Russo G. Lobefaro R, et al. Among authors: garassino mc. Lung Cancer. 2021 Feb;152:165-173. doi: 10.1016/j.lungcan.2020.12.027. Epub 2020 Dec 28. Lung Cancer. 2021. PMID: 33421923
Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients.
Durosini I, Janssens R, Arnou R, Veldwijk J, Smith MY, Monzani D, Smith I, Galli G, Garassino M, Katz EG, Bailo L, Louis E, Vandevelde M, Nackaerts K, de Wit GA, Pravettoni G, Huys I. Durosini I, et al. Front Public Health. 2021 Feb 5;9:622154. doi: 10.3389/fpubh.2021.622154. eCollection 2021. Front Public Health. 2021. PMID: 33634069 Free PMC article.
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
De Toma A, Lo Russo G, Signorelli D, Pagani F, Randon G, Galli G, Prelaj A, Ferrara R, Proto C, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. De Toma A, et al. Among authors: garassino mc. Crit Rev Oncol Hematol. 2021 Apr;160:103299. doi: 10.1016/j.critrevonc.2021.103299. Epub 2021 Mar 16. Crit Rev Oncol Hematol. 2021. PMID: 33722699 Free article. Review.
263 results